Sensei Biotherapeutics, Inc. announced it will present initial safety and pharmacokinetic monotherapy clinical data from its Phase 1/2 trial of SNS- 101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), in a late-breaking poster presentation at the Society for Immunotherapy of Cancer (SITC) 38(th) Annual Meeting, being held in San Diego, Calif., from November 1 - 5, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.79 USD | -45.52% | -48.37% | +14.16% |
May. 14 | Stephens Starts Sensei Biotherapeutics With Overweight Rating, $5 Price Target | MT |
May. 09 | Sensei Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.16% | 36.37M | |
+12.30% | 116B | |
+12.15% | 106B | |
-8.14% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.33% | 16.33B | |
+5.80% | 14.14B | |
+28.03% | 12.02B |
- Stock Market
- Equities
- SNSE Stock
- News Sensei Biotherapeutics, Inc.
- Sensei Biotherapeutics, Inc. to Present Initial Clinical Data from Dose Escalation Trial of SNS 101 At 2023 SITC Annual Meeting